phase 3 (of a clinical trial)sān qī三期clinical triallínchuáng shìyàn临床试验to confirm / to provezhèngshí证实new type / novelxīn xíng新型antihypertensive drugjiàngyā yào降压药baxdrostat (drug name)Bā shā sī tā巴沙司他therapeutic efficacyliáoxiào疗效significant / markedxiǎnzhù显著。
phase 3 (of a clinical trial)
sān qī
三期
clinical trial
línchuáng shìyàn
临床试验
to confirm / to prove
zhèngshí
证实
new type / novel
xīn xíng
新型
antihypertensive drug
jiàngyā yào
降压药
baxdrostat (drug name)
Bā shā sī tā
巴沙司他
therapeutic efficacy
liáoxiào
疗效
significant / marked
xiǎnzhù
显著
to publish
fābiǎo
发表
in / at (formal)
yú
于
New England Journal of Medicine
Xīn Yīnggélán Yīxué Zázhì
新英格兰医学杂志
(relative clause marker)
de
的
phase 3
sān qī
三期
clinical trial
línchuáng shìyàn
临床试验
result
jiéguǒ
结果
to show / to indicate
xiǎnshì
显示
aldosterone synthase
quán gù tóng hé méi
醛固酮合酶
inhibitor
yìzhì jì
抑制剂
baxdrostat
Bā shā sī tā
巴沙司他
for / in terms of
duì
对
treatment-resistant
nán zhì xìng
难治性
hypertension / high blood pressure
gāo xuèyā
高血压
to have / to possess
jùyǒu
具有
significant / marked
xiǎnzhù
显著
therapeutic efficacy
liáoxiào
疗效
approximately
yuē
约
40 percent
40%
40%
(possessive particle)
de
的
medication-taking
yòng yào
用药
patient
huànzhě
患者
blood pressure
xuèyā
血压
to recover / to restore
huīfù
恢复
to / reaching (formal)
zhì
至
healthy
jiànkāng
健康
level
shuǐpíng
水平
US Food and Drug Administration
Měiguó Shípǐn Yàopǐn Jiāndū Guǎnlǐjú
美国食品药品监督管理局
already
yǐ
已
to accept for review
shòulǐ
受理
its (formal)
qí
其
priority review
yōuxiān shěnpíng
优先审评
application
shēnqǐng
申请
expected / anticipated
yùjì
预计
in (formal)
yú
于
the year 2026
2026 nián
2026年
second quarter
dì èr jìdù
第二季度
to make (a decision)
zuòchū
作出
approval
shěnpī
审批
decision
juédìng
决定